Personalised T-Cell Activation Shows Promise in Overcoming Minimal Residual Disease in Chronic Lymphocytic Leukaemia

High-Performance T-Cell Activation in CLL: Study Highlights

This Phase 1 clinical trial represents a significant milestone in the development of personalised immunotherapy for Chronic Lymphocytic Leukaemia (CLL). The study’s primary highlights include:

1. High Immunogenicity: T-cell responses targeting multiple leukaemia-specific peptides were induced in 95% (19 of 20) of participants.
2. Sustained Response: Immune activation persisted in 84% of responders at the six-month follow-up, with increasing response intensity observed over time.
3. Safety Profile: The personalised activator was well-tolerated, with no grade 4 adverse events or treatment-related serious adverse events reported.
4. Synergistic Potential: The study successfully combined personalised vaccination with ongoing Bruton’s tyrosine kinase inhibitor (BTKi) therapy, addressing the challenge of minimal residual disease (MRD).